Please login to the form below
Fovea
This page shows the latest Fovea news and features for those working in and with pharma, biotech and healthcare.
Germany's IQWiG delivers bad news for Bayer’s Eylea
The G-BA had earlier decided that Eylea would be compared to Lucentis in cases of DMO, which affected the fovea centralis - a pit in the back of the eye that ... The data showed no relevant differences between the treatment groups for patients in whom
Latest news
-
NICE gives final backing to drugs from Bayer, GSK and Otsuka
and for whom there is no permanent damage to the part of the eye called the fovea.
-
Eylea set to challenge Lucentis in UK after NICE recommendation
who show signs the condition has been getting worse and for whom there is no permanent damage to the part of the eye called the fovea.
-
S-A signs ophthalmology deal
The ophthalmology division of sanofi-aventis (S-A), Fovea Pharmaceuticals, has signed a co-operation agreement with the Institut de la Vision (page is in French), one of the main eye
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Kala Pharma appoints Fovea founder Bernard Gilly to board
Dr Gilly, along with Professor Jose Sahel and Pierre Belichard, set up Fovea in 2005. ... Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Part 1 of the Medscape video interview series
- NHS England appoints Chris Hopson as its new chief strategy officer
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Kim Lemon appointed head of Liberation Unlimited
- Perrigo expands consumer health with €3.6bn Omega purchase
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- We’ll need more than a spoonful of sugar to counter vaccine hesitancy
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
